Everest Clinical Research, a portfolio company of Washington, D.C.-based private equity firm Arlington Capital Partners, announced on November 7 that it acquired Sofia, Bulgaria-based August Research.
August Research is a contract research organization (CRO) that provides clinical trial services (CTS) and pharmacovigilance services to a variety of pharmaceutical and biotechnology clients. The CRO has worked on more than 120 projects for Phase I-IV clinical trials across multiple therapeutic areas including cardiovascular, infectious disease, oncology and rare disease.
Everest Clinical Research is a full-service CRO providing a range of expertise-based clinical research services to pharmaceutical, biotechnology and medical device industries across the globe.
The acquisition of August Research establishes a European footprint for Everest to provide full-service CTS offerings to its clients, as well as other operational capabilities. The combination of Everest and August Research’s capabilities will provide a global, full suite of clinical services to its client base, accelerating growth opportunities for the merged company.
August Research’s founders Dana Leff Niedzielska and Lukasz Niedzielski, alongside other managing directors in the European offices, will continue as key executive leaders with the business post-transaction. Financial terms were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 36th CRO acquisition of the year. This transaction also marks Everest’s first healthcare acquisition of the year. In December 2022, the company acquired Brightech International, a CRO that specializes in complex, value-add biostatistics, programming and clinical data management services, for an undisclosed price.
